Skip to main content

Table 2 PTV and OAR dosimetry with hydrogel spacer

From: Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes

Organ RTOG 0938 Achieved Dose
Parameters (Gy) (mean±stdev)
PTV
 Maximum point dose (1cc) ≤ 38.78 38.1 ± 0.5
 Minimum dose received by 95% of PTV ≥ 36.25 36.3 ± 0.4
Rectum
 Maximum point dose (1cc) ≤ 38.06 33 ± 3.4
 Less than 3 cc < 34.40 29.5 ± 4.0
 90% rectum ≤ 32.63 25.0 ± 4.4
 80% rectum ≤ 29.00 21.1 ± 4.7
 50% rectum ≤ 18.13 13.5 ± 4.7
Bladder
 Maximum point dose (1cc) ≤ 38.06 37 ± 0.4
 90% bladder ≤ 32.63 22.9 ± 5.7
 50% bladder ≤ 18.13 4.4 ± 3.5
Urethra ≤ 38.78 38 ± 0.4